Stephen J. Farr
Net Worth

Last updated:

What is Stephen J. Farr net worth?

The estimated net worth of Dr. Stephen J. Farr is at least $17,511,747 as of 6 Sep 2025. He owns shares worth $1,483,141 as insider, has earned $3,940,656 from insider trading and has received compensation worth at least $12,087,950 in Zogenix, Inc. and Zogenix, Inc..

What is the salary of Stephen J. Farr?

Dr. Stephen J. Farr salary is $1,020,000 per year as Co-Founder, Chief Executive Officer, Pres & Director in Zogenix, Inc.. He also receives $867,950 as Co-Founder, Chief Executive Officer, Pres & Director in Zogenix, Inc..

How old is Stephen J. Farr?

Dr. Stephen J. Farr is 66 years old, born in 1959.

What stocks does Stephen J. Farr currently own?

As insider, Dr. Stephen J. Farr owns shares in one company:

Company Title Shares Price per share Total value
Zogenix, Inc. (ZGNX) Co-Founder, Chief Executive Officer, Pres & Director 55,590 $26.68 $1,483,141

What does Zogenix, Inc. do?

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

ZGNX logo
ZGNX
Zogenix, Inc.
$26.68

Stephen J. Farr insider trading

Zogenix, Inc.

Dr. Stephen J. Farr has made 7 insider trades between 2014-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 90,313 units of ZGNX stock on 10 Jan 2019. As of 6 Sep 2025 he still owns at least 55,590 units of ZGNX stock.

Transaction Date Security Shares Price per share Total value Source
Option
Restricted Stock Units 16,875 N/A N/A
Option
Common Stock 16,875 N/A N/A
Option
Restricted Stock Units 16,875 N/A N/A
Option
Common Stock 16,875 N/A N/A
Option
Restricted Stock Units 27,500 N/A N/A
Option
Common Stock 27,500 N/A N/A
Sale
Common Stock 6,158 $18.51 $113,966
Option
Stock Option (Right to Buy) 9,661 $10.35 $99,991
Option
Common Stock 9,661 $10.35 $99,991
Option
Common Stock 10,000 N/A N/A
Option
Restricted Stock Units 10,000 N/A N/A
Option
Common Stock 10,000 N/A N/A
Option
Common Stock 34,225 $10.5 $359,191
Sale
Common Stock 34,225 $52.02 $1,780,282
Option
Stock Option (Right to Buy) 34,225 $10.5 $359,191
Option
Stock Option (Right to Buy) 34,225 $10.35 $354,229
Option
Common Stock 34,225 $10.35 $354,229
Sale
Common Stock 34,225 $10.35 $354,229
Option
Common Stock 5,000 $20 $100,000
Option
Stock Option (Right to Buy) 5,000 $20 $100,000
Option
Common Stock 34,225 $17.52 $599,519
Option
Stock Option (Right to Buy) 34,225 $17.52 $599,519
Sale
Common Stock 34,225 $47.98 $1,642,150
Option
Common Stock 5,000 N/A N/A
Option
Restricted Stock Units 5,000 N/A N/A
Sale
Common Stock 312 $20 $6,240
Option
Common Stock 90,313 $36.67 $3,311,507
Option
Stock Option (Right to Buy) 90,313 $36.67 $3,311,507
Option
Stock Option (Right to Buy) 937 $28 $26,236
Option
Common Stock 937 $28 $26,236
Sale
Common Stock 1,612 $2.01 $3,247
Sale
Common Stock 19,288 $2.1 $40,543

Zogenix key executives

Zogenix, Inc. executives and other stock owners filed with the SEC:

  • Dr. Bradley S. Galer (63) Executive Vice President & Chief Medical Officer
  • Dr. Gail M. Farfel (61) Executive Vice President & Chief Devel. Officer
  • Dr. Stephen J. Farr (66) Co-Founder, Chief Executive Officer, Pres & Director
  • Melinda Baker Senior Director of Corporation Communications
  • Mr. Ashish M. Sagrolikar (58) Executive Vice President & Chief Commercial Officer
  • Mr. Bret E. Megargel Vice President of Corporation Devel.
  • Mr. Jeff D. Durflinger Vice President of Technical Operations & Product Supply
  • Mr. Michael P. Smith (57) Executive Vice President, Chief Financial Officer, Treasurer & Sec.
  • Mr. Stephen H. Jenner Vice President of Marketing
  • Ms. Shawnte M. Mitchell Executive Vice President, Gen. Counsel & Sec.